AZENTA Reports Positive Financial Results for Third Quarter of FY2023

August 20, 2023

☀️Earnings Overview

AZENTA ($NASDAQ:AZTA) reported total revenue of USD 165.9 million for the third quarter of FY2023, which is a 25.0% increase from the same period in the prior year. Net income also improved significantly, rising from -9.6 million to -1.5 million. These results were released on June 30th 2023.

Share Price

On Tuesday, AZENTA reported their financial results for the third quarter of fiscal year 2023. The company’s stock opened at $47.5 and closed at $48.0, up by 1.2% from the prior closing price of $47.4. This is a positive sign for AZENTA investors, as it indicates that the company is doing well financially. This is a clear indication of the company’s success and its commitment to delivering positive returns to shareholders.

Overall, AZENTA’s financial results for the third quarter of fiscal year 2023 are encouraging and point to a strong future for the company. Investors can be confident that AZENTA is on track to deliver continued growth and profitability. Live Quote…

About the Company

  • AZENTA_Reports_Positive_Financial_Results_for_Third_Quarter_of_FY2023″>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Azenta. AZENTA_Reports_Positive_Financial_Results_for_Third_Quarter_of_FY2023″>More…

    Total Revenues Net Income Net Margin
    630.28 -38.4 -5.0%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Azenta. AZENTA_Reports_Positive_Financial_Results_for_Third_Quarter_of_FY2023″>More…

    Operations Investing Financing
    -12.79 -45.58 -675.47
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Azenta. AZENTA_Reports_Positive_Financial_Results_for_Third_Quarter_of_FY2023″>More…

    Total Assets Total Liabilities Book Value Per Share
    3.07k 345.92 41.79
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Azenta are shown below. AZENTA_Reports_Positive_Financial_Results_for_Third_Quarter_of_FY2023″>More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -9.5% 5.8% -4.4%
    FCF Margin ROE ROA
    -8.8% -0.6% -0.6%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we’ve analyzed AZENTA‘s financials and based on our Risk Rating, AZENTA is a medium risk investment in terms of financial and business aspects. We’ve detected two risk warnings in their balance sheet and financial journal. To access this information and gain further insight into how AZENTA is doing financially, become a registered user of GoodWhale. Our registration process is simple and fast, so you can get started quickly and start making informed decisions about your investments. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company offers a complete suite of products and services that enable researchers to more effectively understand the function and structure of genomes. Azenta‘s products and services are used by scientists around the world to advance their knowledge of genomics and enable them to make discoveries that improve human health. Azenta is a market leader in genomic solutions, with a strong track record of providing the highest quality products and services to its customers. The company’s products and services are used by scientists around the world to advance their knowledge of genomics and enable them to make discoveries that improve human health. Eurobio Scientific, Straumann Holding AG, and Singular Genomics Systems Inc are all major competitors of Azenta in the genomic solutions market.

    – Eurobio Scientific ($BER:E8TN)

    Eurobio Scientific is a biotechnology company that specializes in the development and commercialization of diagnostic tests and products. The company has a market cap of 198.51M as of 2022 and a Return on Equity of 21.05%. Eurobio Scientific’s products are used in the diagnosis and treatment of diseases, such as cancer, HIV/AIDS, and hepatitis. The company’s products are sold in over 60 countries worldwide.

    – Straumann Holding AG ($LTS:0QMV)

    As of 2022, Straumann Holding AG has a market cap of 18.02B and a Return on Equity of 21.04%. The company is a leading provider of dental implants and other oral health products and services.

    – Singular Genomics Systems Inc ($NASDAQ:OMIC)

    Singular Genomics Systems Inc is a company that focuses on providing genomic solutions. Its market cap as of 2022 is 170.64M, and its ROE is -19.33%. The company’s main products are its sequencing services and its software solutions.


    AZENTA’s financial performance has been positive in the third quarter of FY2023. The company reported total revenue of USD 165.9 million, representing a 25.0% increase from the same period last year. Net income of -1.5 million was a significant improvement from the -9.6 million reported in the comparable period of the previous financial year.

    Investors should take this into consideration when making investment decisions regarding AZENTA. Analysts have predicted that the company’s performance will continue to be strong in the coming quarters, and that the stock can be expected to be an attractive investment opportunity in the near future.

    Recent Posts

    Leave a Comment